Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 214 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Other Advanced Solid Tumors Clear all
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Solid Tumor, Breast Cancer, Colon Cancer, Cholangiocarcinoma, Soft Tissue Sarcoma
Interventions
LY3039478, Taladegib, Abemaciclib, Cisplatin, Gemcitabine, Carboplatin, LY3023414
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Miami, Florida • Detroit, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced May 21, 2026, 6:43 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, MSI-H Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Other Solid Tumors
Interventions
CDX-527
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced May 21, 2026, 6:43 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumours
Interventions
AZD0156, Olaparib, irinotecan, Fluorouracil, Folinic Acid
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2022 · Synced May 21, 2026, 6:43 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Gastrointestinal Neoplasms
Interventions
GSK5764227
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Los Alamitos, California • Whittier, California • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced May 21, 2026, 6:43 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
YL201, YL201 and atezolizumab
Drug
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
19
States / cities
Fair Oaks, California • La Jolla, California • Lone Tree, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced May 21, 2026, 6:43 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Platinum Responsive Malignancies
Interventions
KML-001, Cisplatin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced May 21, 2026, 6:43 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
Interventions
STK-012, pembrolizumab, pemetrexed, carboplatin
Drug
Lead sponsor
Synthekine
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
27
States / cities
Tucson, Arizona • Beverly Hills, California • Fullerton, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced May 21, 2026, 6:43 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Urothelial Carcinoma, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Lung Adenocarcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Urothelial Carcinoma, Refractory Biliary Tract Carcinoma, Refractory Colorectal Carcinoma, Refractory Gastroesophageal Junction Adenocarcinoma, Refractory Lung Adenocarcinoma, Refractory Ovarian Carcinoma, Refractory Pancreatic Carcinoma, Refractory Urothelial Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Devimistat, Fluorouracil, Gemcitabine Hydrochloride, Hydroxychloroquine, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced May 21, 2026, 6:43 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumors, KRAS Mutation
Interventions
BI 1823911, BI 1701963, Midazolam
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
New York, New York • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced May 21, 2026, 6:43 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Acral Lentiginous Melanoma, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, Esophageal Squamous Cell Carcinoma, Urothelial Carcinoma, DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Melanoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer
Interventions
ATRC-101, Pembrolizumab, Pegylated liposomal doxorubicin (PLD)
Biological · Drug
Lead sponsor
Atreca, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced May 21, 2026, 6:43 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ADCT-601, Gemcitabine
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Santa Monica, California • Stanford, California • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced May 21, 2026, 6:43 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors
Interventions
ADI-PEG 20
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced May 21, 2026, 6:43 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Gastrointestinal Malignancies, Solid Tumors
Interventions
Oxaliplatin, Gemcitabine, Capecitabine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced May 21, 2026, 6:43 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
Interventions
YL201, Atezolizumab
Drug
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Houston, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced May 21, 2026, 6:43 PM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Taselisib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 21, 2026, 6:43 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Major Advanced Solid Tumors Other Than Colorectal
Interventions
PM01183
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Aurora, Colorado • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced May 21, 2026, 6:43 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer, Ovarian Epithelial Cancer Recurrent, Sarcoma, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Prostate Cancer, Prostatic Neoplasms
Interventions
Mifepristone and Eribulin in combination
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
11
States / cities
Tucson, Arizona • Tampa, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced May 21, 2026, 6:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma, Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations
Interventions
FT-2102, Azacitidine, Nivolumab, Gemcitabine and Cisplatin
Drug · Biological
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Gilbert, Arizona • Aurora, Colorado • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced May 21, 2026, 6:43 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Small Cell Lung Cancer, Ovarian Cancer, Solid Tumors
Interventions
Topotecan Liposomes Injection (TLI)
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Detroit, Michigan • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced May 21, 2026, 6:43 PM EDT
Enrolling by invitation Phase 1 Interventional
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC), Urothelial Carcinoma Bladder, Gastroesophageal Junction (GEJ) Adenocarcinoma, Esophageal Squamous Cell Cancer, Gastric Cancer, Cancer, Solid Tumors (Phase 1)
Interventions
RNDO-564, Pembrolizumab
Drug
Lead sponsor
Rondo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
San Francisco, California • New Haven, Connecticut • Grand Rapids, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 21, 2026, 6:43 PM EDT
Not yet recruiting Phase 2 Interventional
View directory record Official record
Conditions
Solid Tumors
Interventions
BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC, Temozolomide, Pumitamig, Pemetrexed, Carboplatin, Nab-paclitaxel, Gemcitabine, Paclitaxel
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
18
States / cities
San Francisco, California • Aurora, Colorado • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced May 21, 2026, 6:43 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Interventions
MCLA-129, Osimertinib, Chemotherapy
Drug
Lead sponsor
Merus B.V.
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Orange, California • Nashville, Tennessee • West Valley City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced May 21, 2026, 6:43 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer, Advanced Solid Tumor
Interventions
BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist, Aromatase Inhibitor
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
5
States / cities
Birmingham, Alabama • New Haven, Connecticut • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 21, 2026, 6:43 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
Interventions
GVV858, Fulvestrant, Letrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 21, 2026, 6:43 PM EDT